Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Outperform Rating and 6 Price Target for Geron NASDAQ GERN

Elaine Mendonca by Elaine Mendonca
March 15, 2024
in Breaking News
0
Finance_ stocks to buy
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Wedbush analyst Robert Driscoll has once again expressed confidence in Geron (NASDAQ: GERN), reiterating an Outperform rating and a $6 price target on March 15, 2024. This reaffirmation underscores Wedbush’s optimistic view on Geron’s potential performance, signaling a positive outlook for the stock moving forward.

Geron Corporation (GERN) Stock Skyrockets 82.29% on March 15, 2024: Potential for Growth and Investor Interest

On March 15, 2024, Geron Corporation (GERN) had an impressive performance in the stock market. The stock opened at $3.01, which was $1.26 higher than its previous close. Throughout the day, GERN shares continued to climb, closing at $4.45. This marked a significant increase of $1.44, or 82.29%, from the previous day’s closing price. Investors may have been drawn to GERN on this day due to its strong price momentum and significant price increase. The stock’s performance on March 15th demonstrated that it had the potential for growth and was attracting interest from traders. Investors and analysts may continue to monitor GERN’s performance in the coming days to see if this positive trend continues.

GERN Corporation (GERN) Sees Decrease in Revenue and Net Income, Slight Increase in EPS – March 15, 2024 Update

On March 15, 2024, Geron Corporation (GERN) saw a significant decrease in its total revenue compared to both the previous year and the last quarter. According to data from CNN Money, the total revenue for GERN was $237.00K in the past year, which decreased by 60.23% from the previous year. In the last quarter, the total revenue further decreased to $23.00K, representing an 85.98% decrease from the previous quarter.

The net income for GERN also experienced a decline, with a net loss of -$184.13M in the past year and a net loss of -$51.97M in the last quarter. This represents a 29.76% decrease in net income since the previous year and a 16.0% decrease since the last quarter.

Despite these declines, there was a slight increase in earnings per share (EPS) for GERN. The EPS was -$0.32 in the past year, which increased by 13.39% compared to the previous year. In the last quarter, the EPS remained steady at -$0.09, showing no change from the previous quarter.

Overall, GERN’s stock performance on March 15, 2024, reflected a decrease in total revenue and net income, but a slight increase in earnings per share. Investors will need to closely monitor GERN’s financial performance in the coming quarters.

Tags: GERN
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Renewable energy

CBAK Energy Technology Reports Strong Revenue Growth in Q4 2023

Financing and finances

Analysis of Recent Analyst Ratings and Price Targets for APA

Analyzing Acurx Pharmaceuticals A Look at Past Performance and Future Expectations

Recommended

Torrid Holdings Stock

Torrid Holdings Faces Critical Earnings Test

5 months ago
Take-Two Stock

Take-Two Shares in Holding Pattern as Investors Await GTA VI Details

6 months ago
Union Pacific Stock

Union Pacific’s Future Hangs in Balance as Historic Railroad Merger Faces Critical Vote

4 months ago
Biotechnology Markets and money

BioTechnes Quarterly Earnings and Stock Performance Analysis

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Claros Mortgage Trust Secures Financial Flexibility Through Strategic Debt Overhaul

Trending

Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

by SiterGedge
February 7, 2026
0

The integration of Vigil Neuroscience into French pharmaceutical giant Sanofi has been finalized. This strategic move, which...

Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Potbelly Stock

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success
  • Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com